Idiopathic Pulmonary Fibrosis

Ofev Shown to Slow Idiopathic Pulmonary Fibrosis Progression Long-Term

Ofev Shown to Slow Idiopathic Pulmonary Fibrosis Progression Long-Term

By

The primary objective was to characterize the long-term safety and tolerability of Ofev in patients with IPF; efficacy endpoints included annual rate of decline in forced vital capacity (FVC) calculated over 192 weeks.

No Benefit From Nintedanib Plus Sildenafil in Idiopathic Pulmonary Fibrosis

No Benefit From Nintedanib Plus Sildenafil in Idiopathic Pulmonary Fibrosis

By

Nintedanib plus sildenafil did not improve St. George's Respiratory Questionnaire scores in patients with idiopathic pulmonary fibrosis.

Idiopathic Pulmonary Fibrosis and GERD: An Unclear Connection

Idiopathic Pulmonary Fibrosis and GERD: An Unclear Connection

By

Although gastroesophageal reflux disease and idiopathic pulmonary fibrosis may be related, the association between the 2 disorders is most likely confounded by smoking.

FDA Fast-Tracks Pamrevlumab for Idiopathic Pulmonary Fibrosis

FDA Fast-Tracks Pamrevlumab for Idiopathic Pulmonary Fibrosis

By

The FDA's designation was based on data from a Phase 2 placebo-controlled trial that demonstrated pamrevlumab could potentially address an unmet medical need for this condition.

Laparoscopic Antireflux Surgery for Treating Idiopathic Pulmonary Fibrosis

Laparoscopic Antireflux Surgery for Treating Idiopathic Pulmonary Fibrosis

By

Laparoscopic antireflux surgery was safe and well tolerated in patients with idiopathic pulmonary fibrosis and abnormal acid gastroesophageal reflux.

Interstitial Lung Disease Diagnosis Improved Using Rheumatologic Assessment

Interstitial Lung Disease Diagnosis Improved Using Rheumatologic Assessment

By

Adding routine rheumatologic assessments to interstitial lung disease diagnosis could reduce the need for invasive procedures and improve diagnostic accuracy.

Anti-Fibrotic Drug Gets Orphan Drug Status for Idiopathic Pulmonary Fibrosis

Anti-Fibrotic Drug Gets Orphan Drug Status for Idiopathic Pulmonary Fibrosis

By

Targeting TGF-β signaling in a tissue-specific manner allows the drug to modulate the fibrotic cascade with maximum clinical effects while avoiding adverse events.

Nintedanib and Pirfenidone Tolerated in Idiopathic Pulmonary Fibrosis

Nintedanib and Pirfenidone Tolerated in Idiopathic Pulmonary Fibrosis

By

Many patients with idiopathic pulmonary fibrosis in an international phase 4 study tolerated combination therapy with pirfenidone and nintedanib.

Lung Transplant Survival Lower During Acute Exacerbations of IPF

Lung Transplant Survival Lower During Acute Exacerbations of IPF

By

Compared with individuals who had stable idiopathic pulmonary fibrosis, those with an acute exacerbation had a significantly shorter survival, especially at the 3 year follow-up.

Recombinant Human Pentraxin 2 Slowed Lung Function Decline in IPF

Recombinant Human Pentraxin 2 Slowed Lung Function Decline in IPF

By

Recombinant human pentraxin 2 therapy resulted in a slower decline in lung function in patients with idiopathic pulmonary fibrosis.

Idiopathic Pulmonary Fibrosis Outcomes Improved by Gastroesophageal Reflux Treatment

Idiopathic Pulmonary Fibrosis Outcomes Improved by Gastroesophageal Reflux Treatment

By

Treatment for gastroesophageal reflux significantly reduced mortality in idiopathic pulmonary fibrosis and improved transplant-free survival.

Treatment for Idiopathic Pulmonary Fibrosis Gets Orphan Drug Designation

Treatment for Idiopathic Pulmonary Fibrosis Gets Orphan Drug Designation

By

RP5063 is a new chemical entity with a novel mechanism of multimodal modulation of serotonin and dopamine signaling pathways.

Thyroid hormone supplementation may be a promising treatment for idiopathic pulmonary fibrosis [PreClinical]

An enzyme involved in thyroid hormone activation was found to be elevated in patients with pulmonary fibrosis.

Improving Prognosis in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension

Improving Prognosis in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension

By

Bosentan may benefit a subset of patients with idiopathic pulmonary fibrosis-associated pulmonary hypertension.

Chronic Lung Disease Research in the Pipeline: An Interview With Augustine M.K. Choi, MD

Chronic Lung Disease Research in the Pipeline: An Interview With Augustine M.K. Choi, MD

Pulmonology Advisor sits down with Augustine M.K. Choi, MD, Stephen and Suzanne Weiss Dean of Weill Cornell Medicine to discuss the latest topics in pulmonary medicine.

Examining the Efficacy of Carbon Monoxide Therapy in Idiopathic Pulmonary Fibrosis: An Interview With Augustine M.K. Choi, MD

Examining the Efficacy of Carbon Monoxide Therapy in Idiopathic Pulmonary Fibrosis: An Interview With Augustine M.K. Choi, MD

Pulmonology Advisor sits down with Augustine M.K. Choi, MD, Stephen and Suzanne Weiss Dean of Weill Cornell Medicine to discuss the latest topics in pulmonary medicine.

Identifying New Therapeutics for Pulmonary Diseases: An Interview With Augustine M.K. Choi, MD

Identifying New Therapeutics for Pulmonary Diseases: An Interview With Augustine M.K. Choi, MD

Pulmonology Advisor sits down with Augustine M.K. Choi, MD of Stephen and Suzanne Weiss Dean of Weill Cornell Medicine to discuss the latest topics in pulmonary medicine.

Overview of Autophagy Research in COPD: An Interview With Augustine M.K. Choi, MD

Overview of Autophagy Research in COPD: An Interview With Augustine M.K. Choi, MD

Pulmonology Advisor sits down with Augustine M.K. Choi, MD, Stephen and Suzanne Weiss Dean of Weill Cornell Medicine to discuss the latest topics in pulmonary medicine.

Azithromycin Improves Survival in Idiopathic Pulmonary Fibrosis

Azithromycin Improves Survival in Idiopathic Pulmonary Fibrosis

By

Azithromycin may be an effective treatment option for acute exacerbation of idiopathic pulmonary fibrosis.

Mechanical Ventilation Increases Costs and Mortality in IPF

Mechanical Ventilation Increases Costs and Mortality in IPF

By

Mechanical ventilation does not improve outcomes in IPF patients, lengthens hospital stays, and increases costs.

Diagnostic Performance of Idiopathic Pulmonary Fibrosis Algorithm

Diagnostic Performance of Idiopathic Pulmonary Fibrosis Algorithm

The idiopathic pulmonary fibrosis algorithm has a sensitivity of 55.6% and positive predictive value of 42.2%.

Predicting Survival in IPF With CT-Measured Pulmonary Artery: Aorta Ratio

Predicting Survival in IPF With CT-Measured Pulmonary Artery: Aorta Ratio

By

Computed tomography-derived pulmonary artery-to-aorta ratio can predict pulmonary artery pressure and survival in patients with idiopathic pulmonary fibrosis.

Predicting Survival Trajectories in IPF Using 2 T-Cell Biomarkers

Predicting Survival Trajectories in IPF Using 2 T-Cell Biomarkers

By

Researchers found a significant association with declining forced vital capacity and diffusing capacity of the lung for carbon monoxide with ICOS and CD28.

Sign Up for Free e-newsletters